Laidlaw & Co. Initiates Coverage On Soleno Therapeutics with Buy Rating

Laidlaw & Co. analyst Yale Jen initiates coverage on Soleno Therapeutics (NASDAQ:SLNO) with a Buy rating.

Benzinga · 12/23/2019 15:29

Laidlaw & Co. analyst Yale Jen initiates coverage on Soleno Therapeutics (NASDAQ:SLNO) with a Buy rating.